PEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Penumbra Inc (PEN) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown strong financial performance and positive revenue growth, the pending acquisition by Boston Scientific introduces uncertainty regarding future growth and independence. Additionally, the technical indicators and options data do not strongly support an immediate buy decision.
The MACD histogram is negative (-3.692) but contracting, indicating a potential slowdown in the bearish momentum. The RSI is neutral at 28.887, suggesting no clear overbought or oversold conditions. The stock is trading near its S1 support level (338.947), which could act as a short-term floor, but the overall trend lacks strong bullish signals.
Strong financial performance in Q3 2025, with revenue growth of 17.82% YoY, net income growth of 55.28% YoY, and EPS growth of 56.00% YoY. Gross margin also improved to 67.78%. Analysts have raised price targets recently, reflecting optimism about the company's fundamentals and sector trends.
The pending acquisition by Boston Scientific has led to downgrades from analysts, citing limited upside potential post-acquisition. Technical indicators do not show strong bullish momentum, and options data suggests short-term bearish sentiment. Lack of recent news or significant trading trends among hedge funds and insiders.
In Q3 2025, Penumbra reported revenue of $354.69M, up 17.82% YoY. Net income increased to $45.85M, up 55.28% YoY. EPS rose to 1.17, up 56.00% YoY. Gross margin improved to 67.78%, up 1.86% YoY, indicating strong operational efficiency.
Recent analyst ratings have been mixed. While some firms have raised price targets (e.g., JPMorgan to $370, BofA to $370), others have downgraded the stock to Neutral or Hold due to the pending acquisition. The consensus price target is around $374, slightly above the current pre-market price of $338.72.
